Community Spotlight LuMind IDSC names new Director of Community Programs Following a five-month, national search, LuMind IDSC Down Syndrome Foundation announced the appointment of Christina…Kate O’NeillSeptember 21, 2023
Community SpotlightResearch NewsResearch Spotlight Boston Globe OpEd People with Down Syndrome Now Left Out of Treatment LuMind IDSC and The Arc of Northeast collaborated on an OpEd that was recently published…Kate O’NeillSeptember 18, 2023
Community SpotlightResearch News Key updates on Down syndrome community access to new Alzheimer’s drugs Five takeaways for the Down syndrome community: Updates on accessing the new Alzheimer’s drugsLuMind IDSC…Kate O’NeillJuly 7, 2023
Research NewsResearch Spotlight LuMind IDSC statement on FDA approval of Leqembi LuMind IDSC issues statement following FDA full approval of Leqembi™ to treat early-stage Alzheimer’s disease …Kate O’NeillJuly 7, 2023
Community Spotlight Meet the Black Down Syndrome Association by guest contributor, Crystal Lotterberry, co-founder of the Black Down Syndrome Association About the Black…Kate O’NeillJuly 7, 2023
Press ReleaseResearch News MapHabit Study: Assistive Technology Has Positive Outcomes for Children with Down Syndrome Study Finds Assistive Technology Has Positive Outcomes for Children with Down Syndrome and Their Caregivers …Kate O’NeillJune 2, 2023
Research NewsPress ReleaseResearch Spotlight Expert panel addresses inequitable access to Alzheimer’s drugs for adults with Down syndrome Seeking to rectify existing federal and state policies which prevent people with intellectual disabilities from…Kate O’NeillJune 1, 2023
Community Spotlight LuMind IDSC joins Advocacy Day on Capitol Hill In April, leaders from LuMind IDSC joined with 350 self-advocates, caregivers, and professionals to meet…Kate O’NeillMay 12, 2023
Research NewsResearch Spotlight LuMind IDSC Statement re: Donanemab Phase 3 Results Pharmaceutical company Eli Lilly today announced results of a phase III clinical trial that proves…Kate O’NeillMay 3, 2023
Research SpotlightResearch NewsSleep Apnea Important progress in the treatment of sleep apnea and Down syndrome At the end of March, the US Food & Drug Administration approved Inspire’s Hypoglossal Nerve…Kate O’NeillMarch 29, 2023